{
    "nct_id": "NCT04592198",
    "official_title": "A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg for the Prevention of CINV in Cancer Patients Receiving MEC",
    "inclusion_criteria": "* With histologically or cytologically confirmed malignant disease;\n\n  -. Be scheduled to receive the first course of MEC to be administered on Day 1\n* Using reliable contraceptive measures;\n* negative serum pregnancy test (if potentially child bearing)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received investigational drugs within 30 days before the start of study treatment or scheduled to receive a highly or moderately emetogenic chemotherapeutic agent;\n* Have a clinically unstable seizure disorder with seizure activity requiring anticonvulsant medication;\n* Have severe renal or hepatic impairment;\n* Have positive serology test results;\n* Have a known contraindication to 5-HT3 receptor antagonists;\n* Treated with commercially available or investigative palonosetron formulation within 2 weeks prior to start of study treatment;\n* Allergic to palonosetron or any other 5-HT3 antagonist;\n* Currently a user of any recreational or illicit drugs (including marijuana) or has current evidence of drug or alcohol abuse or dependence as determined by the investigator;\n* Will be receiving stem cell rescue therapy in conjunction with study related course of emetogenic chemotherapy;\n* Received or will receive total body irradiation or radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 and/or during the diary reporting period.",
    "miscellaneous_criteria": ""
}